The ovarian cancer condition center is a comprehensive resource for clinical news and expert insights on ovarian cancer. Read more at OncLive.
May 1st 2024
Yang Yang Hartwich, PhD discusses a study delving into the mechanisms underlying chemoresistance in ovarian cancer.
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
April 30th 2024
Gottfried Konecny, MD, discusses the importance of evaluating PROs in patients with platinum-resistant ovarian cancer receiving mirvetuximab soravtansine.
April 29th 2024
Gottfried E. Konecny, MD, discusses PRO data for mirvetuximab soravtansine derived from the phase 3 MIRASOL trial.
Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.
April 27th 2024
Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.
April 26th 2024
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
April 25th 2024
Thomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.
Gottfried Konecny, MD, discusses patient-reported outcomes from the phase 3 MIRASOL trial in platinum-resistant ovarian cancer.
April 23rd 2024
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.
Don S. Dizon, MD, FACP, FASCO, discusses future directions for precision medicine approaches in ovarian cancer.
April 22nd 2024
Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer.
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
April 18th 2024
Naomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.
April 17th 2024
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the phase 3 ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.
April 16th 2024
Erin K. Crane, MD, MPH, discusses the impact of the phase 3 PRIMA trial on second-line maintenance approaches in ovarian cancer.
April 15th 2024
Núria Agustí Garcia, MD, discusses the MELISA trial, which is evaluating further steps toward lymphadenectomy replacement in ovarian cancer.
April 14th 2024
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.
April 13th 2024
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.
April 12th 2024
Gabriella Smith, MD, discusses the predictive value of KELIM for survival outcomes with HIPEC at the time of surgery in epithelial ovarian cancer.